Latest Regulatory Pathways News

Optiscan Imaging Ltd has launched its first in-human breast cancer study and unveiled a new veterinary imaging device, while securing a key US collaboration to support FDA submissions.

Superior Resources Limited has expanded its copper exploration strategy to include high-grade copper-gold targets alongside porphyry prospects, while progressing the Steam Engine Gold Project towards early production within two years.

American Rare Earths Limited reports strong progress at its Halleck Creek Rare Earths Project, highlighted by exceptional sampling results, key permitting milestones, and a $15 million equity raise to fund development.

Neurotech International reports encouraging Phase I human pharmacokinetic results for its pediatric cannabinoid drug NTI164, alongside published clinical trial data in Rett Syndrome and key regulatory progress in the US and Australia.

Bio-Gene Technology Limited has secured $2.45 million to fund critical safety studies and scale-up production of its novel insecticides Flavocide and Qcide, positioning the company for upcoming regulatory approvals and commercial partnerships.

Western Yilgarn NL has significantly expanded its bauxite portfolio with the acquisition of the Cardea projects, lifting its total JORC bauxite resources to 188 million tonnes, while also securing a promising new gold project in Western Australia’s Gascoyne region.

Admiralty Resources has obtained temporary road transport approval in Chile, enabling the shipment of up to 150,000 tonnes of iron ore concentrate from its Mariposa project. This milestone advances the project closer to full production amid ongoing regulatory progress.

ReNerve Limited reported a robust 53% increase in annual revenue, driven by strategic partnerships and new regulatory approvals that broaden its global footprint in nerve repair.

Vital Metals Limited has released a comprehensive Scoping Study for its Tardiff Rare Earths deposit in Canada, revealing strong economic potential with an 11-year mine life and significant neodymium-praseodymium resources.

Syntara Limited reports encouraging Phase 2 data for its lead drug amsulostat in myelofibrosis, secures FDA Fast Track status, and expands clinical programs into myelodysplastic syndrome and keloid scars.

Immutep Limited advances its pivotal Phase III lung cancer trial and reports promising results across multiple oncology and autoimmune programs, supported by a solid cash position to fund operations through 2026.

EMVision Medical Devices reports strong progress in its pivotal trial for the emu™ bedside brain scanner and successful aeromedical testing of its First Responder device, backed by a $5 million government grant and $10.5 million in cash reserves.